Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) — Analysis Summary
Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) has a market cap of $44.15B with year-over-year revenue growth of +1.3%. Net margin stands at 15.2%. The stock trades at a P/E ratio of 19.9.
Key Takeaways
- Revenue changed +1.3% year-over-year
- Net margin of 15.2%
- P/E ratio of 19.9
Compared with its sector, HLN posted revenue growth of +1.3% and trades at a P/E of 19.9.
Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Current ratio at 0.92x — current liabilities exceed current assets
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Employees
24,524
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$0.13
Dividend Yield
1.27%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.